Publish in this journal
Journal Information
Vol. 62. Issue 9.
Pages 1022-1031 (September 2009)
Download PDF
More article options
Vol. 62. Issue 9.
Pages 1022-1031 (September 2009)
DOI: 10.1016/S1885-5857(09)73268-2
Full text access
High-Density Lipoprotein Cholesterol and Cardiovascular Disease in Spanish Hypertensive Women. The RIMHA Study
Colesterol HDL y enfermedad cardiovascular en mujeres hipertensas de España. Estudio RIMHA
Antonio Cocaa, Luis Cea-Calvob, José V. Lozanoc, Verónica Inarajab, Cristina Fernández-Pérezd, Jorge Navarroe, Álvaro Bonete, Josep Redónf
a Unidad de Hipertensión Arterial, Servicio de Medicina Interna General, Instituto de Medicina y Dermatología, Hospital Clínic (IDIBAPS), Universidad de Barcelona, Barcelona, Spain
b Departamento de Investigación Clínica, Merck Sharp & Dohme de España, Madrid, Spain
c Centro de Salud Serrería 2, Valencia, Spain
d Unidad de Apoyo a la Investigación, Hospital Clínico Universitario San Carlos, Universidad Complutense de Madrid, Madrid, Spain
e Centro de Salud Salvador Pau, Valencia, Spain
f Unidad de Hipertensión Arterial, Hospital Clínico Universitario, Universidad de Valencia, Valencia, Spain
This item has received
Article information
Figures (2)
Tables (5)
TABLE 1. Characteristics of the Total Sample, and Stratified According to Whether the Serum Concentration of High-Density Lipoprotein (HDL) Cholesterol Was Normal or Low
TABLE 2. Multivariate Analysis. Variables Independently Associated With the Presence of Low Concentrations of High-Density Lipoprotein Cholesterol
TABLE 3. Odds Ratio (OR) of Cardiovascular Disease and Heart Disease in Women With Low Concentrations of High-Density Lipoprotein (HDL) Cholesterol Compared With Women With Normal Concentrations of HDL Cholesterol. Multivariate Analysis
TABLE 4. Prevalence of Cardiovascular Disease by Quintiles of High-Density Lipoprotein (HDL) Cholesterol
TABLE 5. Multivariate Analysis. Odds Ratio (OR) of Cardiovascular Disease and Heart Disease According to the Concentration of High-Density Lipoprotein (HDL) Cholesterol
Show moreShow less
Introduction and objectives. To determine the prevalence of a low high-density lipoprotein cholesterol (HDL-C) concentration in 11 042 hypertensive Spanish women aged ≥55 years, to identify factors associated with a low concentration, and to evaluate its relationship with cardiovascular disease (CVD). Methods. Analysis of RIMHA cross-sectional study findings. Data on demographic, biochemical and clinical variables were obtained. Relationships between a low HDL-C concentration ( <46 mg dl and cvd between the hdl-c concentration in quintiles were studied by multivariate logistic regression modeling results prevalence of a low was 24 3 95 confidence interval ci 23 5 minus 25 1 higher women with diabetes or independently associated excess weight smoking presence inversely age 7 vs 18 4 those normal p <.001). There was an independent association between a low HDL-C concentration and CVD after adjustment for other risk factors (odds ratio [OR]=1.42; 95% CI, 1.26−1.60; P<.001) and with silent target organ damage (OR=1.31; 95% CI, 1.15−1.49; P<.001). Similarly, there was an independent inverse association between the HDL-C concentration (in quintiles) and the prevalence of CVD, particularly for HDL-C concentrations <58 mg dl conclusions one in 4 hypertensive women aged ge 55 years had a low hdl-c concentration which was independently associated with the presence of cvd moreover there an inverse association between and prevalence even at normal concentrations
High-density lipoprotein cholesterol
Cardiovascular disease
Cross-sectional studies
Introducción y objetivos. Evaluar la prevalencia de concentración baja de colesterol de las lipoproteínas de alta densidad (cHDL), los factores asociados y la relación con la enfermedad cardiovascular (ECV), en 11.042 mujeres hipertensas de 55 o más años de edad. Métodos. Análisis del estudio transversal RIMHA. Se recogieron datos demográficos, bioquímicos, y clínicos. Se analizó la relación entre cHDL bajo ( < 46 mg/dl) y ECV, y entre concentración de cHDL (quintiles) y ECV mediante modelos multivariables de regresión logística. Resultados. La prevalencia de cHDL bajo fue del 24,3% (intervalo de confianza [IC] del 95%, 23,5-25,1), y fue mayor en mujeres diabéticas o con ECV. El cHDL bajo se asoció a exceso de peso, tabaquismo, diabetes y ECV, e inversamente con la edad. La prevalencia de ECV fue mayor en mujeres con cHDL bajo (el 24,7 frente al 18,4% con cHDL normal; p < 0,001). Se observó una asociación independiente entre cHDL bajo y ECV tras ajustar por otros factores de riesgo (odds ratio [OR] = 1,42; IC del 95%, 1,26-1,60; p < 0,001) y por la lesión asintomática de órgano diana (OR = 1,31; IC del 95%, 1,15-1,49; p < 0,001). Del mismo modo, se observó una asociación independiente e inversa entre la concentración de cHDL (quintiles) y la presencia de ECV, en especial para concentraciones de cHDL < 58 mg/dl. Conclusiones. En esta muestra de mujeres hipertensas de 55 años o más, una de cada 4 tenía cHDL bajo, y esto se relacionó independientemente con la presencia de ECV. Además, encontramos una asociación inversa entre la concentración de cHDL y la prevalencia de ECV también en cifras de cHDL consideradas normales.
Palabras clave:
Colesterol de las lipoproteínas de alta densidad
Enfermedad cardiovascular
Estudios transversales
Full Text


Cardiovascular disease (CVD) is the leading cause of death in older women in developed societies, and the number of deaths is expected to increase by 30% from the 1990s to 2020.1 Ischemic heart disease becomes more common after the menopause, and could therefore be partly related with the associated metabolic changes, in particular increases in concentrations of total cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides, and reductions in the concentration of high-density lipoprotein (HDL) cholesterol, which can contribute to the increased cardiovascular risk in women aged 60 years or older.2,3

For several years now low concentrations of HDL cholesterol have been known to be associated with an increased risk of developing CVD, especially coronary heart disease.4,5 This increased risk remains in persons treated with statins,6 even when very low concentrations of LDL cholesterol are achieved.7

Thus, the low concentration of HDL cholesterol may be a conditioning factor for the persistence of the cardiovascular risk, at least in certain patients, in spite of treatment with statins. In addition, HDL cholesterol seems to have a greater impact in women. In the Framingham study, the risk of developing myocardial infarction associated with a low HDL cholesterol concentration was far greater in women than in men,8 and in 4 American studies an increase in HDL cholesterol produced a greater cardiovascular benefit in women than in men.9

Only a few series have studied the prevalence of low concentrations of HDL cholesterol in Spanish women and the transverse association between HDL cholesterol and CVD. The aim of this study was to evaluate the prevalence of low concentrations of HDL cholesterol and the association between the HDL cholesterol concentration and the prevalence of CVD in a wide sample of women aged ≥55 years with hypertension in cluded in the RIMHA study (Riesgo de Ictus en las Mujeres con Hipertensión Arterial— Risk of stroke in women with hypertension).10


This study is an analysis of the RIMHA study, which is a cross-sectional, multicenter, epidemiological study undertaken in primary care centers in Spain.10 The study was approved by an independent clinical research ethics committee and the data were collected between June and December 2004. Each researcher collected information about the first 8 non-selected hypertensive women who attended their office, after being duly informed and providing signed consent to participation in the study.

The primary endpoint of the study was to estimate the risk of stroke in this particular population, and the results have already been published.10 Amongst the secondary aims of the study was the evaluation of other cardiovascular risk factors. The study included women who had had hypertension for at least 6 months (according to the diagnosis in their clinical histories) and were aged ≥55 years. Patients were excluded if they refused to give informed consent or had a disease or psychological disorder advising against their participation. Information was gathered about demographic and anthropometric data, cardiovascular risk factors and diseases.

The blood pressure was measured with an OMRON® M5 automatic device following the recommendations in force at the time.11 All the patients underwent an electrocardiogram. Left ventricular hypertrophy was considered to be present when the Cornell voltage criteria for women were fulfilled.12 A woman was considered to be diabetic if this diagnosis was reflected in the clinical history or if her baseline fasting glucose level was above 125 mg/dL.

The biochemical data were obtained from a blood test undergone within the 6 months prior to data collection. If this had not been done, or if the patient had started a new treatment since then that could affect the result, a new blood test was carried out. The glomerular filtration rate was calculated with the shortened MDRD (Modification of Diet in Renal Disease) equation.13

The measurement of the lipids was done at the usual laboratory for each office, not centralized. In general, the total cholesterol and the triglyce-rides were measured by enzymatic assays, the HDL cholesterol by a direct in vitro enzymatic method, and the LDL cholesterol was calculated from the Friedewald formula. To define the HDL cholesterol concentration as low, we used a concentration of <46 mg/dL, a concentration that the European Guidelines on Cardiovascular Prevention define as a marker of increased cardiovascular risk in women.14

Statistical Analysis

The sample size was calculated according to the primary endpoint of the study.10 According to the likelihood of the expected risk of stroke taken from the Framingham study, with a 95% confidence interval and a maximum sampling error of 0.41%, we estimated a sample of 9200 women.10

The qualitative variables are presented as their frequency dis tribution. The quantitative variables are summarized as their mean and standard deviation (SD). For the comparison of the means between the groups, we used the Student t test for independent groups, and for the association between categorical variables we used the c2 test or Fisher's exact test. HDL cholesterol was managed as a binary variable ("normal" or "low" HDL cholesterol) to make the comparison between the two groups, and then in quintiles according to the HDL cholesterol concentration.

The variables associated with a low concentration of HDL cholesterol were evaluated with a multivariate logistic regression model that included demographic and metabolic variables and CVD. Another two models were used to study the association between low concentrations of HDL cholesterol and CVD, with CVD being the dependent variable; the variable HDL cholesterol was again binary ("normal" or "low" HDL cholesterol) and, alternatively, as quintiles of HDL cholesterol. The adjustment variables selected were statins and those variables that could affect the presence of CVD. These models were also repeated taking as the dependent variable the presence of heart disease (excluding cerebrovascular disease). The odds ratios (OR) and their 95% confidence intervals (CI) are given. In all the comparisons, a null hypothesis was rejected if the alpha error was less than 0.05. The data were processed using the statistical program SPSS 13.0.


Population Characteristics

In total, 11 042 women (85.8% of the total sample) had a complete lipid profile available (mean age, 67.9 years; 20% with established CVD) (Table 1). No significant differences were found between the women included and those excluded from the analysis.

HDL Cholesterol Concentration and Prevalence of Low HDL Cholesterol

The mean (SD) concentration of HDL cholesterol was 55.9 (14.6) mg/dL. This concentration was lower in the diabetic women (53.5 [14.7] vs 56.9 [14.5] mg/ dL in the non-diabetic women; P<.001), in women with prior CVD (54.3 [15.7] vs 56.3 [14.3] mg/dL in women without CVD; P<.001) and in women treated with statins (55.2 [15] vs 56.5 [14.5] mg/dL in the non-treated women; P<.001).

The prevalence of low concentrations of HDL cholesterol (<46 mg/dL) was 24.3% (95% CI, 23.5-25.1). The prevalence was higher in the diabetic women as compared with the non-diabetic women (29.9% vs 21.9%; P<.001), in the women with CVD (30.1% vs 22.8% in the women without CVD; P<.001) and in the women treated with sta tins as compared with the women not treated with statins (26.9% vs 22.2%; P<.001). For a cut-off point of <50 mg/dL, the prevalence was 36% (95% CI, 35.1-36.9).

The prevalence was greater for the age range of 55-69 years (26.9%, 26.2%, and 25.8%, res pectively, in the women younger than 60, aged 60-64, and 65-69 years), and lower in the older women (22.5%, 20.9%, and 20.6%, respecti vely, in the women aged 70-74, 75-79 years, and 80 years or over; c2 for the linear trend <0.001). In each age range the prevalence was greater in diabetic women and in women with CVD (Figures 1 and 2) (c2 for the linear trend <0.001 in all cases, except in the women with diabetes, P=.004).

Figure 1. Percentage of hypertensive women with high-density lipoprotein (HDL) cholesterol concentrations <46 mg/dL, stratified according to age and the presence or absence of diabetes mellitus.

Figure 2. Percentage of hypertensive women with high-density lipoprotein (HDL) cholesterol concentrations <46 mg/dL, stratified according to age and the presence or absence of cardiovascular disease.

Among the women without CVD, the prevalence of low concentrations of HDL cholesterol was similar in those with and without treatment with diuretics or beta-blockers (22.9% and 22.8%, respectively; P=.919), whereas in the women with CVD the prevalence was numerically superior in the treated women, though the difference was not statistically significant (31.6% vs 27.8%; P=.062). In the non-diabetic women, the prevalences were 21.9% and 22% (without and with treatment with diuretics or beta-blockers; P=.894), and for the diabetic women the figures were 27.8% and 31.6% (without and with treatment with diuretics or beta-blockers, respectively, P=.032).

Prevalence of High Triglyceride Levels

Triglyceride levels were ≥150 mg/dL in 38.2% of the patients, a prevalence that was greater in the women with low concentrations of HDL cholesterol (56.5% vs 32.3% in the women with normal HDL cholesterol; P<.001), in the diabetic women (48.3% vs 34%; P<.001) and in the women with CVD (44.7% vs 36.5%; P<.001).

Characteristics Related With Low HDL Cholesterol Concentrations

Table 1 shows the characteristics of the women with normal and low HDL cholesterol concentrations. The group with low HDL cholesterol concentrations contained a greater percentage of women who were smokers, or who had obesity, a large abdominal circumference and diabetes me llitus, and a worse blood pressure control. In the women with low HDL cholesterol concentrations, the concentration of total cholesterol was slightly lower, that of LDL cholesterol slightly higher and that of triglycerides higher. The prevalence of high concentrations of triglycerides was much greater in the women with low HDL cholesterol concentrations. Finally, the women with low HDL cholesterol concentrations had a greater prevalence of left ventricular hypertrophy, a low glomerular filtration rate, overall CVD and heart disease.

The variables related with low concentrations of HDL cholesterol were evaluated in a multivariate model with the following variables: age, menopause, body mass index, waist circumference, diabetes mellitus, smoking and CVD (Table 2). The presence of low concentrations of HDL cholesterol was associated with excess weight, diabetes, smoking and CVD and, inversely, with age. In the women without CVD, the related variables were the same and the magnitude of the association was si milar (Table 2). The inclusion in the multivariate models of treatment with diuretics or beta- blockers did not modify the associations, and the presence of a low concentration of HDL cholesterol was not related with these treatments.

Relation Between Low HDL Cholesterol Concentrations and Cardiovascular Disease

The prevalence of overall CVD was greater in the women with low HDL cholesterol concentrations as compared with those with HDL cholesterol concentrations in the range of normality (24.7% vs 18.4%; P<.001) (Table 1). After excluding cerebrovascular disease, the prevalences of heart disease were 20.6% (women with low HDL cholesterol concentrations) and 14.5% (women with normal HDL cholesterol concentrations; P<.001). Table 3 shows the OR of CVD and heart disease in the women with low HDL cholesterol concentrations compared with the women with normal HDL cholesterol concentrations obtained from the multivariate models. The first model included the variables age; smoking; diabetes; body mass index, categorized as normal, overweight or obese; blood pressure con trol; LDL cholesterol; treatment with statins and HDL cholesterol concentration (low or normal). There was an independent association between a low HDL cholesterol concentration and CVD (OR of CVD in women with a low HDL cholesterol concentration =1.42; 95% CI, 1.26-1.60, as compared with women with a normal HDL cholesterol concentration; P<.001). The OR of heart disease, excluding cerebrovascular disease, was similar (Table 3). The inclusion in this model of triglycerides (normal or raised) did not modify the relation between low HDL cholesterol concentrations and CVD, although there was a slight relation between triglycerides ≥150 mg/ dL and CVD (OR=1.14; 95% CI, 1.02-1.27).

The second model included the same variables together with left ventricular hypertrophy and glomerular filtration rate (normal or reduced). The associations between low HDL cholesterol concentrations and CVD and between low HDL cholesterol concentrations and heart disease remained significant (Table 3). Nor did the inclusion of triglycerides change the association between low HDL cholesterol concentrations and CVD, but in this second model no asso ciation was seen between high concentrations of triglycerides and CVD.

Relation Between HDL Cholesterol Concentration and Cardiovascular Disease

To evaluate the association between the concentration of HDL cholesterol and CVD, the population was divided into the following quintiles of HDL cholesterol: <45 mg/dL (first), 45-50 mg/dL (second), 51-58 mg/dL (third), 59-66 mg/dL (fourth), and >66 mg/dL (fifth). The prevalence of CVD was highest in the lowest quintile of cholesterol (25.5%) and lowest in the higher quintiles of HDL cholesterol (c2 for the linear trend, <0.001). The prevalence of heart disease showed the same linear trend, as did the prevalence of each individual entity, except for stroke (Table 4).

Finally, the association between the con centration of HDL cholesterol and the prevalence of CVD or heart disease was analyzed using the same multivariate models, introducing the HDL cholesterol in quintiles. Taking as the reference the women with the highest HDL cholesterol concentration (fifth quintile, >66 mg/dL), the OR of CVD and heart disease increased progressively with lower concentrations of HDL cholesterol (Table 5). Compared with the women with the highest concentrations of HDL cholesterol (>66 mg/dL), those with the lowest HDL cholesterol concentration (<45 mg/dL) had an adjusted OR of CVD that was 60% greater (OR=1.59; 95% CI, 1.35-1.88; P<.001). The addition of left ventricular hypertrophy and glomerular filtration rate barely modified the relation (Table 4), which began to be significant for an HDL cholesterol concentration <58 mg/dL.


One out of every 4 women with hypertension aged ≥55 years had a low concentration of HDL cholesterol, and this was associated with a greater prevalence of overall CVD, and heart disease in particular. The varia bles associated with a low HDL cholesterol concentration were excess weight, diabetes, smoking and a history of CVD. In spite of the effect of diuretics and beta-blockers on the lipids, we found no relation between treatment with these drugs and the presence of low HDL cholesterol concentrations, probably because, in the context of the effect of multiple variables, their influence is lower.

Most studies that have reported the prevalence of low HDL cholesterol concentrations in our setting have done so in the context of the metabolic syndrome (cut-off point in women of <50 mg/dL). Given this, the studies have reported prevalences of low HDL cholesterol concentrations of 34.4% in patients with CVD (men, 27.8%; women, 52%),15 of 23.3% in hypertensive persons aged over 55 years (men, 13.3%; women, 31.1%)16 and lower in persons of working age, although with a prevalence >30% in women.17 Using these same criteria, the prevalence in patients with dyslipidemia was 35.4% (39% in women) in a European study,18 whereas in the United States, in the NHANES study, it was 37.1% (39.3% in women).19

We found a prevalence of low HDL cholesterol concentrations of 24.3% for a cut-off point of <46 mg/dL and 36% for a cut-off point of <50 mg/ dL, in line with earlier studies. The prevalence was higher in the women who had a greater cardiovascular risk (in diabetics and women with a history of CVD). Although persons living in Mediterranean areas have higher concentrations of HDL cholesterol, probably related with their dietary habits,20 specific groups with a high cardiovascular risk, such as those described, have a considerably higher prevalence of low HDL cholesterol concentrations.

The association between low HDL cholesterol concentrations and CVD or heart disease was independent of other risk factors. Moreover, the association between the HDL cholesterol concentration and CVD or heart disease was also seen for a few HDL cholesterol concentra tions situated within the range of normality (in particular, below 58 mg/ dL) where the OR of CVD increased significantly after adjusting the model for all the risk factors and target organ damage. The inverse continuous relation between the HDL cholesterol concentra tion and the risk of CVD has been described in follow-up studies such as the Framingham study,4 particularly in women. In the women of the Framingham study the adjusted risk of having a myocardial infarction in the lowest quartile of HDL cholesterol (<47 mg/ dL) was 6 times greater than in the top quartile (≥67 mg/dL), with the risk increasing much more than that for the men.8

The cardiovascular risk associated with low concentra tions of HDL cholesterol should be interpreted in the context of the high prevalence of the metabolic syndrome in the group of hypertensive women with low HDL cholesterol concentrations (91.4%) (Table 1). Many studies have shown that this particular group of metabolic anomalies increases the risk of developing CVD21-23 and, in addition, the low HDL cholesterol concentration usually coincides with high concentrations of triglycerides. In our study, the in clusion in the models of triglycerides did not modify the relation between low HDL cholesterol concentrations and CVD; in fact, the relation between triglycerides and CVD was weaker, and even disappeared when target organ damage was added to the model. Whereas a low HDL cholesterol concentration is a well-established cardiovascular risk factor, studies on triglycerides and CVD have found less consistent relations, although postprandial hypertriglyceridemia is emerging as an independent risk factor, especially in women.24,25

The protective properties of HDL cholesterol are well-known. As well as participating in the inverse transport of cholesterol for its hepatic elimination, HDL particles possess antioxidant, anti-inflammatory and antithrombotic properties that protect against the development of atherosclerosis and CVD.26-29 A combined analysis of 4 follow-up studies showed that an increment of 1 mg/dL in levels of HDL cholesterol was associated with a reduction in the incidence of coronary heart disease of 2% in men and 3% in women.9 Even so, the evidence that increasing HDL cholesterol concentrations by the use of drugs can reduce cardiovascular risk is modest. Earlier studies with gemfibrozil30 and with niacin (the most effective drug for increasing HDL cholesterol)31 indicate that the cardiovascular benefits of these drugs are closely related with the increase in HDL cholesterol. A recent meta-analysis of 23 clinical trials found that the trials in which LDL cholesterol decreased at the same time as HDL cholesterol increased were those that achieved the greatest reduction in cardiovascular risk.32 Large clinical trials are currently in progress involving patients with a high cardiovascular risk in order to assess whether the addition of fenofibrate33 or extended-release niacin34,35 to statins reduces the incidence of cardiovascular complications. These clinical trials may determine whether the pharmacologic increase in HDL cholesterol reduces the incidence of CVD in patients already receiving statins, and what is the most suitable concentration of HDL cholesterol to achieve with drugs in high cardiovascular risk patients.

Several limitations should be considered concerning this study. The first is its cross-sectional nature, which prevents the establishment of a cause-effect relation between the associations found. The second limitation concerns the sample selection method, which was consecutive and not random, resulting in the greater likelihood of inclusion of patients with disease processes. Thirdly, the original study did not collect data about treatment with fibrates or physical activity, which may slightly increase HDL cholesterol concentrations, and we were not therefore able to analyze their importance in the multivariate model. However, these limitations should have no impact on the relation seen between HDL cholesterol concentrations and the prevalence of CVD. Finally, the analyses were not performed at a centralized laboratory. We cannot therefore rule out the possibility of a certain degree of variability in the measurements or that this may have influenced the results. Nevertheless, we believe that the sample size analyzed and the analysis methods used strengthen the study, and that the results complement the information from follow-up studies and clinical trials, as they highlight the problems faced by physicians in their daily clinical practice. In spite of having been undertaken in a sample of women with hypertension, the prevalence of hypertension is so high in the age group studied36,37 that the results of this study can be applied to most women of a similar age.


One out of every 4 hypertensive women aged 55 years or over seen in primary care offices had low HDL cholesterol concentrations. The prevalence of low HDL cholesterol concentrations was greater in women with an increased cardiovascular risk and was independently associated with the presence of CVD and heart disease. Moreover, the inverse association between HDL cholesterol concentrations and the prevalence of CVD was found at figures currently considered to be normal. The results of large ongoing clinical trials with HDL cholesterol-raising drugs should better determine the effect on CVD of pharmacologically increasing HDL cholesterol concentrations, and the attitude to follow in patients with low HDL cholesterol concentrations, particularly in those with a high cardiovascular risk.


The RIMHA study was supported by the Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA) and the Socie dad Española de Medicina Rural y Generalista (SEMER GEN), and was financed by a research grant from Merck Sharp & Dohme de España. The authors of the manuscript wish to thank the study researchers for their participation.

CVD: cardiovascular disease
HDL: high-density lipoprotein
LDL: low-density lipoprotein

The present study was financed with a research grant from Merck Sharp & Dohme de España. Two of the authors (Luis Cea-Calvo and Verónica Inaraja) work full time in the Clinical Research Department of Merck Sharp & Dohme de España.

Correspondence: Prof. A. Coca.
Unidad de Hipertensión Arterial. Hospital Clínic. Villarroel, 170. 08036 Barcelona. España.

Received October 7, 2008.
Accepted for publication May 26, 2009.

Yusuf S, Reddy S, Ounpuu S, Anand S..
Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization..
Circulation, 104 (2001), pp. 2746-53
Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR..
Menopause and risk factors for coronary heart disease..
N Engl J Med, 321 (1989), pp. 641-6
Matthews KA, Kuller LH, Sutton-Tyrrell K, Chang Y-F..
Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women..
Stroke, 32 (2001), pp. 1104-11
Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR..
High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study..
Am J Med, 62 (1977), pp. 707-14
Assmann G, Schulte H, von Eckardstein A, Huang Y..
High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport..
Atherosclerosis, 124 Suppl (1996), pp. S11-20
Chapman M..
Beyond LDL cholesterol reduction: the way ahead in managing dyslipidaemia..
Eur Heart J, 7 Suppl (2005), pp. F56-62
Barter P, Gotto A, LaRosa J, Maroni J, Szarek M, Grundy SM, et al..
HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events..
N Engl J Med, 357 (2007), pp. 1301-10
Abbott RD, Wilson PW, Kannel WB, Castelli WP..
High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction: the Framingham Study..
Atherosclerosis, 8 (1988), pp. 207-11
Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al..
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies..
Circulation, 79 (1989), pp. 8-15
Coca A, Redón J, Cea-Calvo L, Lozano JV, Navarro J, Fernández-Pérez C, et al..
Estimated risk of a first stroke and conditioning factors in Spanish hypertensive women. The RIMHA study..
Blood Press, 15 (2006), pp. 237-44
2003 European Society of Hypertension-European Society of Cardiology guidelines for management of arterial hypertension J Hypertens..
, 21 pp. 1011-53
Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P..
Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings..
Circulation, 75 (1987), pp. 565-72
Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al..
National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification..
Ann Intern Med, 139 (2003), pp. 137-47
Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)..
European guidelines on cardiovascular disease prevention in clinical practice: executive summary..
Eur Heart J, 28 (2007), pp. 2375-414
Palma Gámiz JL, Conget Donlo I, Bertomeu González V, Ascaso Gimilio JF, González Juanatey JR, Alegría Ezquerra E, et al..
Prevalencia del síndrome metabólico en pacientes con enfermedad cardiovascular en España: estudio CLYDIA..
Med Clin (Barc), 128 (2007), pp. 407-13
Navarro J, Redón J, Cea-Calvo L, Lozano JV, Fernández-Pérez C, Bonet A, et al..
Metabolic syndrome, organ damage and cardiovascular disease in treated hypertensive patients. The ERIC-HTA study..
Blood Press, 16 (2007), pp. 20-7
Alegría E, Cordero A, Laclaustra M, Grima A, León M, Casasnovas JA, et al..
Prevalencia del síndrome metabólico en población laboral española: registro MESYAS..
Rev Esp Cardiol, 58 (2005), pp. 797-806
Bruckert E, Baccara-Dinet M, McCoy F, Chapman J..
High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients..
Curr Med Res Opin, 21 (2005), pp. 1927-34
Ford ES, Giles WH, Dietz WH Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey..
, 287 (2002), pp. 356-9
Estruch R, Martínez-González MA, Corella D, Salas-Salvadó J, Ruiz-Gutiérrez V, Covas MI, et al..
Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial..
Ann Intern Med, 145 (2006), pp. 1-11
Lakka HA, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilheto J, et al..
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men..
JAMA, 288 (2002), pp. 2709-16
Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H..
Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study..
Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, et al..
Prognostic value of the metabolic syndrome in essential hypertension..
J Am Coll Cardiol, 43 (2004), pp. 1817-22
Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM..
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women..
JAMA, 298 (2007), pp. 309-16
Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A..
Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women..
JAMA, 298 (2007), pp. 299-308
Luengo E..
Biología y metabolismo de las HDL. In: González-Juanatey JR, editor..
Lipoprote??nas de alta densidad,
Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM..
Antiinflammatory properties of HDL..
Mineo C, Deguchi H, Griffin JH, Shaul PW..
Endothelial and antithrombotic actions of HDL..
Tomás M, Latorre G, Sentí M, Marrugat J..
The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis..
Rev Esp Cardiol, 57 (2004), pp. 557-69
Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, et al..
Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial..
JAMA, 285 (2001), pp. 1585-91
Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al..
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease..
N Engl J Med, 345 (2001), pp. 1583-92
Brown BG, Hinckley SK, Zhao XQ..
Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials..
Curr Op Lipid, 17 (2006), pp. 631-6
Action to Control Cardiovascular Risk in Diabetes: ACCORD Clinicaltrials..
gov, NCT00000620 [cited Oct 1 2008]. Available from: http://www..
clinicaltrials, (gov/ct2/show/NCT00000620),
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE Clinicaltrials..
gov, NCT00461630 [cited Oct 1 2008]. Available from: http://www..
clinicaltrials, (gov/ct/ show/ NCT00461630?order=1),
Niacin Plus Statin to Prevent Vascular Events AIM-HIGH.., NCT00120289 [cited Oct 1 2008]. Available from: http://www..
Redon J, Cea-Calvo L, Lozano JV, Marti-Canales JC, Llisterri JL, Aznar J, et al..
Blood pressure and estimated risk of stroke in the elderly population of Spain: the PREV-ICTUS Study..
Banegas JR, Rodríguez-Artalejo F, Ruilope LM, Graciani A, Luque M, de la Cruz-Troca JJ, et al..
Hypertension magnitude and management in the elderly population of Spain..
J Hypertens, 20 (2002), pp. 2157-64
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.